Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Pharmaceutical Industry’s Profit Rises 40 Percent In First Five Months Of 2008

This article was originally published in PharmAsia News

Executive Summary

National Development and Reform Commission figures show that for the first five months of 2008, the pharmaceutical industry recorded a gross industrial output value of 311.6 billion yuan ($45.6 billion) and a profit of 27.8 billion yuan ($4.07 billion), up 29 percent and 43.6 percent respectively from the same period last year. The profit represents 22.7 percentage points higher than the national industry average, placing the sector third in the country's 12 major industries. Pharmaceutical raw materials overtook Chinese patent medicine as the second largest profit source for the sector. NDRC sees continuous rapid growth with investment returns improving. However, the industry faces major challenges such as soaring raw material prices for energy, blood product shortages and need for standardized distribution control, as well as slowdown in investment. (Click here for more - Chinese Language)

You may also be interested in...



Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

With $850m, Nuvation Aims To Speed Novel Cancer Drugs To Patients

Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.

US FDA Investigators Focusing Inspections On Aseptic Processing Operations

US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel